Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)

被引：10

作者：

Nicum, S. ^{[1
]}

Holmes, J. ^{[2
]}

McGregor, N. ^{[3
]}

Dunn, R. ^{[3
]}

Collins, L. ^{[3
]}

Kaye, S. ^{[4
]}

McNeish, I. ^{[5
]}

Glasspool, R. M. ^{[6
,7
]}

Hall, M. ^{[8
]}

Roux, R. ^{[1
]}

Michael, A. ^{[9
]}

Banerjee, S. ^{[10
]}

Kristeleit, R. ^{[11
,12
]}

Jayson, G.

Clamp, A. ^{[13
,14
]}

Mansouri, A. ^{[2
]}

机构：

[1] Oxford Univ Hosp NHS Fdn Trust, Dept Oncol, Oxford, England

[2] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Ctr Stat Med CSM, Oxford Clin Trials Res Unit, Oxford, England

[3] Univ Oxford, Dept Oncol, Oncol Clin Trials Off, Oxford, England

[4] Royal Marsden Hosp, Dept Med, Sutton, Surrey, England

[5] Imperial Coll London, Dept Surg & Canc, Ovarian Canc Act Res Ctr, London, England

[6] Univ Glasgow, Beatson West Scotland Canc Ctr, NHS Greater Glasgow & Clyde, Glasgow, Lanark, Scotland

[7] Univ Glasgow, Glasgow, Lanark, Scotland

[8] Mt Vernon Canc Ctr, Dept Med Oncol, Middlesex, England

[9] Univ Surrey, Dept Clin & Expt Med, Surrey, England

[10] Royal Marsden NHS Fdn Trust, Res Lead Gynaecol Unit, London, England

[11] Guys & St Thomas NHS Fdn Trust, UCL Canc Inst, London, England

[12] Guys & St Thomas NHS Fdn Trust, UCLH Dept Oncol, London, England

[13] Univ Manchester, Christie NHS Fdn Trust, Manchester Canc Res Ctr, Manchester, Lancs, England

[14] Univ Manchester, Manchester, Lancs, England

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1165

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

722O

引用

页码：S725 / S726

页数：2

共 50 条

[1] Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
Mansouri, Anita
McGregor, Naomi
Dunn, Rachel
Dobbie, Sam
Holmes, Jane
Collins, Linda
Nicum, Shibani
[J]. BMJ OPEN, 2021, 11 (01):
[2] Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
Shibani Nicum
Naomi McGregor
Rachel Austin
Linda Collins
Susan Dutton
Iain McNeish
Rosalind Glasspool
Marcia Hall
Rene Roux
Agnieszka Michael
Andrew Clamp
Gordon Jayson
Rebecca Kristeleit
Susana Banerjee
Anita Mansouri
[J]. British Journal of Cancer, 2024, 130 : 941 - 950
[3] Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
Nicum, Shibani
Mcgregor, Naomi
Austin, Rachel
Collins, Linda
Dutton, Susan
Mcneish, Iain
Glasspool, Rosalind
Hall, Marcia
Roux, Rene
Michael, Agnieszka
Clamp, Andrew
Jayson, Gordon
Kristeleit, Rebecca
Banerjee, Susana
Mansouri, Anita
[J]. BRITISH JOURNAL OF CANCER, 2024, 130 (06) : 941 - 950
[4] OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinumresistant ovarian cancer
Nicum, S.
Strauss, V. Y.
McGregor, N.
McNeish, I.
Roux, R.
Hall, M.
Michael, A.
Roberts, C.
[J]. ANNALS OF ONCOLOGY, 2017, 28
[5] Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer
Colombo, Nicoletta
Tomao, Federica
Panici, Pierluigi Benedetti
Nicoletto, Maria Ornella
Tognon, Germana
Bologna, Alessandra
Lissoni, Andrea Alberto
DeCensi, Andrea
Lapresa, Mariateresa
Mancari, Rosanna
Palaia, Innocenza
Tasca, Giulia
Tettamanzi, Francesca
Alvisi, Maria Francesca
Rulli, Eliana
Poli, Davide
Carlucci, Luciano
Torri, Valter
Fossati, Roldano
Biagioli, Elena
[J]. GYNECOLOGIC ONCOLOGY, 2022, 164 (03) : 505 - 513
[6] BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer
Colombo, N.
Nicoletto, O.
Panici, P. Benedetti
Tognon, G.
Lissoni, A. A.
Bologna, A.
Tomao, F.
Fossati, R.
Tettamanzi, F.
Rulli, E.
Galli, F.
Alvisi, M. F.
Torri, V.
Biagioli, E.
[J]. ANNALS OF ONCOLOGY, 2018, 29
[7] Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)
Lee, J-M.
Miller, A.
Rose, P.
AlHilli, M.
Washington, C.
John, V.
Shah, C.
Matsuo, K.
Siedel, J.
Miller, D. S.
Chan, J.
Hopp, E.
Kohn, E. C.
Moore, K. N.
Liu, J. F.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S511 - S511
[8] Clinical and molecular characteristics of AMBITION patients who received olaparib plus cediranib or olaparib plus durvalumab for homologous recombination repair mutated, platinum-resistant ovarian cancer (KGOG 3045)
Kim, Se Ik
Joung, Je-Gun
Park, Eunhyang
Lee, Jung-Yun
Choi, Chel Hun
Kim, Sunghoon
Kim, Jae-Weon
Kim, Byoung-Gie
[J]. GYNECOLOGIC ONCOLOGY, 2022, 166 : S23 - S23
[9] OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel plus /- novel agents in platinum-resistant ovarian cancer: Vistusertib
Banerjee, S.
Lewsley, L-A.
Clamp, A. R.
Krell, J.
Herbertson, R.
Glasspool, R. M.
Orbegoso, C.
Green, C.
Kristeleit, R. S.
Gourley, C.
Cambell, C.
Banerji, U.
Shepherd, C.
Brugger, W.
Chudleigh, L.
Hanif, A.
McNeish, I. A.
Paul, J.
[J]. ANNALS OF ONCOLOGY, 2019, 30 : 403 - +
[10] A phase Ib/II trial with expansion of patients at the MTD trial of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.
Rivkin, Saul E.
Iriarte, Desiree
Sloan, Heather
Wiseman, Cara
Moon, James
Goodman, Gary E.
Bondurant, Amy
Veljovich, Daniel
Jiang, Peter Y. Z.
Wahl, Tanya A.
Shah, Chirag
Drescher, Charles
Kaplan, Henry G.
Peters, William A.
Ellis, Erin
Fer, Mehmet F.
Park, Min S.
Johnston, Eileen
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →